B-cell Translocation Gene 1 is Downregulated by Promoter Methylation in Ovarian Carcinoma

Overview

Journal J Cancer

Specialty Oncology

Date 2017 Sep 21

PMID 28928854

Citations 7

Authors

Ji-Ye Kim

Sung-Im DO

Go Eun Bae

Hyun-Soo Kim

Affiliations

Soon will be listed here.

Abstract

A better understanding of tumor biology is important in the identification of molecules that are downregulated in malignancy and in determining their role in tumor suppression. B-cell translocation gene 1 (BTG1) has been shown to act as a tumor suppressor in several types of human malignancy. In this study, we analyzed BTG1 expression in ovarian carcinoma cell lines, and we investigated the mechanism underlying the observed alterations. The methylation status of the promoter region was determined by methylation-specific polymerase chain reaction, and the effect of demethylation on BTG1 expression was analyzed. BTG1 protein expression in ovarian high-grade serous carcinoma tissue samples was evaluated using immunohistochemistry. BTG1 mRNA and protein expression were reduced in ovarian carcinoma cells. In BTG1-silenced ovarian cancer cells, the promoter was highly methylated. Treatment with 5-aza-deoxycytidine significantly elevated BTG1 mRNA and protein expression. Immunostaining demonstrated that BTG1 expression was significantly lower in ovarian carcinoma tissue samples than nonpathological ovaries and fallopian tubes. We demonstrated that BTG1 silencing in ovarian carcinoma occurs through epigenetic repression and is involved in the ovarian carcinogenesis. Our data suggest that BTG1 is a potential therapeutic target for patients with ovarian carcinoma.

Citing Articles

The roles of mRNA expression in cancers: A bioinformatics analysis.

Zheng H, Xue H, Zhang C, Shi K, Zhang R Front Genet. 2022; 13:1006636.

PMID: 36339000 PMC: 9633688. DOI: 10.3389/fgene.2022.1006636.

BTG1 Overexpression Might Promote Invasion and Metastasis of Colorectal Cancer Decreasing Adhesion and Inducing Epithelial-Mesenchymal Transition.

Zhao S, Xue H, Hao C, Jiang H, Zheng H Front Oncol. 2020; 10:598192.

PMID: 33330092 PMC: 7729016. DOI: 10.3389/fonc.2020.598192.

Role of DNA Methylation in the Resistance to Therapy in Solid Tumors.

Romero-Garcia S, Prado-Garcia H, Carlos-Reyes A Front Oncol. 2020; 10:1152.

PMID: 32850327 PMC: 7426728. DOI: 10.3389/fonc.2020.01152.

Identification of BTG1 Status in Solid Cancer for Future Researches Using a System Review and Meta-analysis.

Chen X, Meng F, Xiong H, Wang Y, Tang W, Zou Y Curr Med Sci. 2020; 40(1):85-94.

PMID: 32166669 DOI: 10.1007/s11596-020-2150-z.

microRNA-27a-3p Down-regulation Inhibits Malignant Biological Behaviors of Ovarian Cancer by Targeting BTG1.

Li E, Han K, Zhou X Open Med (Wars). 2019; 14:577-585.

PMID: 31410369 PMC: 6689206. DOI: 10.1515/med-2019-0065.

References

Guehenneux F, Duret L, Callanan M, Bouhas R, Hayette S, Berthet C . Cloning of the mouse BTG3 gene and definition of a new gene family (the BTG family) involved in the negative control of the cell cycle. Leukemia. 1997; 11(3):370-5. DOI: 10.1038/sj.leu.2400599. View

Sun G, Lu Y, Cheng Y, Hu W . The expression of BTG1 is downregulated in NSCLC and possibly associated with tumor metastasis. Tumour Biol. 2013; 35(4):2949-57. DOI: 10.1007/s13277-013-1379-6. View

Agathocleous M, Harris W . Metabolism in physiological cell proliferation and differentiation. Trends Cell Biol. 2013; 23(10):484-92. DOI: 10.1016/j.tcb.2013.05.004. View

Sun G, Lu Y, Cheng Y, Yang C, Liu Q, Jing S . Expression of BTG1 in hepatocellular carcinoma and its correlation with cell cycles, cell apoptosis, and cell metastasis. Tumour Biol. 2014; 35(12):11771-9. DOI: 10.1007/s13277-014-2298-x. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Yoon N, Kim J, Kim H . Clinical outcomes of advanced-stage glassy cell carcinoma of the uterine cervix: a need for reappraisal. Oncotarget. 2016; 7(48):78448-78454. PMC: 5346652. DOI: 10.18632/oncotarget.12905. View

Sun G, Liu Q, Cheng Y, Hu W . B cell translocation gene 1 reduces the biological outcome of kidney cancer through induction of cell proliferation, cell cycle arrest, cell apoptosis and cell metastasis. Int J Mol Med. 2015; 35(3):777-83. DOI: 10.3892/ijmm.2014.2058. View

Shibata D, Aaltonen L . Genetic predisposition and somatic diversification in tumor development and progression. Adv Cancer Res. 2000; 80:83-114. DOI: 10.1016/s0065-230x(01)80013-0. View

Rouault J, Rimokh R, Tessa C, Paranhos G, Ffrench M, Duret L . BTG1, a member of a new family of antiproliferative genes. EMBO J. 1992; 11(4):1663-70. PMC: 556617. DOI: 10.1002/j.1460-2075.1992.tb05213.x. View

10.

Zheng H, Li J, Shen D, Yang X, Zhao S, Wu Y . BTG1 expression correlates with pathogenesis, aggressive behaviors and prognosis of gastric cancer: a potential target for gene therapy. Oncotarget. 2015; 6(23):19685-705. PMC: 4637314. DOI: 10.18632/oncotarget.4081. View

11.

Kim H, Yoon G, DO S, Kim S, Kim Y . Down-regulation of osteoprotegerin expression as a novel biomarker for colorectal carcinoma. Oncotarget. 2016; 7(12):15187-99. PMC: 4924779. DOI: 10.18632/oncotarget.7885. View

12.

Piek J, van Diest P, Verheijen R . Ovarian carcinogenesis: an alternative hypothesis. Adv Exp Med Biol. 2008; 622:79-87. DOI: 10.1007/978-0-387-68969-2_7. View

13.

Berthet C, Guehenneux F, Revol V, Samarut C, Lukaszewicz A, Dehay C . Interaction of PRMT1 with BTG/TOB proteins in cell signalling: molecular analysis and functional aspects. Genes Cells. 2002; 7(1):29-39. DOI: 10.1046/j.1356-9597.2001.00497.x. View

14.

Kanda M, Oya H, Nomoto S, Takami H, Shimizu D, Hashimoto R . Diversity of clinical implication of B-cell translocation gene 1 expression by histopathologic and anatomic subtypes of gastric cancer. Dig Dis Sci. 2014; 60(5):1256-64. DOI: 10.1007/s10620-014-3477-8. View

15.

Wu X, Ding N, Hu W, He J, Xu S, Pei H . Down-regulation of BTG1 by miR-454-3p enhances cellular radiosensitivity in renal carcinoma cells. Radiat Oncol. 2014; 9:179. PMC: 4252025. DOI: 10.1186/1748-717X-9-179. View

16.

Kurman R, Shih I . The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010; 34(3):433-43. PMC: 2841791. DOI: 10.1097/PAS.0b013e3181cf3d79. View

17.

Bandera C . Advances in the understanding of risk factors for ovarian cancer. J Reprod Med. 2005; 50(6):399-406. View

18.

Sun G, Wang Y, Cheng Y, Hu W . The expression of BTG1 is downregulated in nasopharyngeal carcinoma and possibly associated with tumour metastasis. Mol Biol Rep. 2014; 41(9):5979-88. DOI: 10.1007/s11033-014-3475-0. View

19.

Sun G, Wang Y, Cheng Y, Hu W . BTG1 underexpression is an independent prognostic marker in esophageal squamous cell carcinoma. Tumour Biol. 2014; 35(10):9707-16. DOI: 10.1007/s13277-014-2245-x. View

20.

Lee E, Muller W . Oncogenes and tumor suppressor genes. Cold Spring Harb Perspect Biol. 2010; 2(10):a003236. PMC: 2944361. DOI: 10.1101/cshperspect.a003236. View